499 related articles for article (PubMed ID: 33759683)
1. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
[TBL] [Abstract][Full Text] [Related]
2. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
[TBL] [Abstract][Full Text] [Related]
3. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
[TBL] [Abstract][Full Text] [Related]
4. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort.
Schots L; Soenen R; Blanquart B; Thomas D; Lambert J
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):698-710. PubMed ID: 36562700
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
[TBL] [Abstract][Full Text] [Related]
6. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
7. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD
Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207
[TBL] [Abstract][Full Text] [Related]
9. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
Liu M; Wang H; Liu L; Cui S; Huo X; Xiao Z; Zhao Y; Wang B; Zhang G; Wang N
Front Immunol; 2022; 13():1046352. PubMed ID: 36389759
[TBL] [Abstract][Full Text] [Related]
10. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
Ohata C; Ohyama B; Katayama E; Nakama T
J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
[TBL] [Abstract][Full Text] [Related]
12. Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.
Huang D; Yu Y; Lu J; Tan F; Shi Y
Front Med (Lausanne); 2023; 10():1280965. PubMed ID: 38020100
[TBL] [Abstract][Full Text] [Related]
13. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study.
Kridin K; Schonmann Y; Tzur Bitan D; Damiani G; Peretz A; Weinstein O; Cohen AD
Am J Clin Dermatol; 2021 Sep; 22(5):709-718. PubMed ID: 34060006
[TBL] [Abstract][Full Text] [Related]
16. Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections.
Bruno M; Davidson L; Koenen HJPM; van den Reek JMPA; van Cranenbroek B; de Jong EMGJ; van de Veerdonk FL; Kullberg BJ; Netea MG
J Invest Dermatol; 2022 Nov; 142(11):2929-2939.e8. PubMed ID: 35662644
[TBL] [Abstract][Full Text] [Related]
17. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
Egeberg A; Bryld LE; Skov L
J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
[TBL] [Abstract][Full Text] [Related]
19. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
